QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma

Clinical trial NCT06852456 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06852456
Sponsor: Qilu Pharmaceutical Co., Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Start date: 2025-03-01
Primary completion: 2030-12-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.